Multiple analysts predict blockbuster sales revenue for BioMarin Pharmaceutical Inc.’s Voxzogo (vosoritide), the first drug approved in the US for achondroplasia, but company executives guided to a slow ramp-up due to the complications of being first to market in a rare disease during an investor call.
Voxzogo, a C-type natriuretic peptide (CNP) analog injected daily, obtained accelerated approval from the US Food and Drug Administration on...